Aegerion Pharmaceuticals
AEGR
AEGR was delisted on the 29th of November, 2016.
131 hedge funds and large institutions have $1.24B invested in Aegerion Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 50 increasing their positions, 29 reducing their positions, and 32 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
72% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 29
13% more capital invested
Capital invested by funds: $1.09B → $1.24B (+$144M)
2% more funds holding
Funds holding: 129 → 131 (+2)
6% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 32
39% less call options, than puts
Call options by funds: $32M | Put options by funds: $52.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$65.9M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$18.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.6M |
| 4 |
HM
HealthCor Management
New York
|
+$14.4M |
| 5 |
Morgan Stanley
New York
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$38M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$13.3M |
| 3 |
TCM
Tamarack Capital Management
Carlsbad,
California
|
-$11.7M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$10.8M |
| 5 |
FAM
Fred Alger Management
New York
|
-$6.46M |
AEGR Hedge Fund Activity: Q3 2014 in Review
131 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q3 2014, worth a combined $1.24B — up 13% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new AEGR positions and 32 closed out — a net gain of 2 holders — while 50 added to existing stakes and 29 trimmed.
The largest buyer was Scopia Capital Management, adding an estimated $65.9M. The largest seller was Lord, Abbett & Co, cutting an estimated $38M.
- 131 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q3 2014, up from 129 in Q2 2014.
- Funds reported $1.24B of Aegerion Pharmaceuticals stock for Q3 2014, up 13% quarter-over-quarter.
- 34 funds opened new Aegerion Pharmaceuticals positions in Q3 2014 and 32 closed out, a net change of +2 holders.
- The largest Aegerion Pharmaceuticals buyer in Q3 2014 was Scopia Capital Management, an estimated $65.9M added.
- The largest Aegerion Pharmaceuticals seller in Q3 2014 was Lord, Abbett & Co, an estimated $38M sold.
Based on aggregated 13F filings for Q3 2014.